ARS Pharmaceuticals, Inc. (SPRY) Q1 2024 Earnings
SPRY·Reported May 9, 2024·Before market open
Diluted EPS came in at $-0.11.
Diluted EPS
$-0.11met estimate
Consensus: $-0.11
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about ARS Pharmaceuticals, Inc.'s Q1 2024 earnings report.
ARS Pharmaceuticals, Inc. (SPRY) reported Q1 2024 earnings on May 9, 2024 before market open.
ARS Pharmaceuticals, Inc. reported diluted EPS of $-0.11 for Q1 2024.
EPS beat the consensus estimate of $-0.11 by $0.00.
You can read the 10-Q periodic report (0000950170-24-056967) directly on SEC EDGAR. The filing index links above go to sec.gov.